ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /反応

2-Chloro-5-(difluoromethoxy)pyrimidine → (-)-4-(4,4-Difluorocyclohexyl)-2-{1-[5-(difluoromethoxy)pyrimidin-2-yl]piperidin-4-yl}-3-{fluoro[4-(trifluoromethyl)phenyl]methyl}-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol

HRID 715883
ノート
印刷プレビュー

反応式

HRID 715883 の反応式
Cl[C:2]1[N:7]=[CH:6][C:5]([O:8][CH:9]([F:11])[F:10])=[CH:4][N:3]=1.ClC1N=CC(OC2CCN(C)CC2)=CN=1.[F:27][C:28]1([F:74])[CH2:33][CH2:32][CH:31]([C:34]2[C:43]3[CH:42]([O:44]CC4C=CC(OC)=CC=4)[CH2:41][C:40]([CH3:55])([CH3:54])[CH2:39][C:38]=3[N:37]=[C:36]([CH:56]3[CH2:61][CH2:60][NH:59][CH2:58][CH2:57]3)[C:35]=2[CH:62]([F:73])[C:63]2[CH:68]=[CH:67][C:66]([C:69]([F:72])([F:71])[F:70])=[CH:65][CH:64]=2)[CH2:30][CH2:29]1>>[F:74][C:28]1([F:27])[CH2:33][CH2:32][CH:31]([C:34]2[C:43]3[CH:42]([OH:44])[CH2:41][C:40]([CH3:54])([CH3:55])[CH2:39][C:38]=3[N:37]=[C:36]([CH:56]3[CH2:61][CH2:60][N:59]([C:2]4[N:7]=[CH:6][C:5]([O:8][CH:9]([F:11])[F:10])=[CH:4][N:3]=4)[CH2:58][CH2:57]3)[C:35]=2[CH:62]([F:73])[C:63]2[CH:68]=[CH:67][C:66]([C:69]([F:71])([F:72])[F:70])=[CH:65][CH:64]=2)[CH2:30][CH2:29]1
参加物実験手順後処理出典と根拠反応ノート

参加物

4

反応物 3

HCID 574765572-Chloro-5-(difluoromethoxy)pyrimidineHCID 86682426(-)-4-(4,4-Difluorocyclohexyl)-3-{fluoro[4-(trifluoromethyl)phenyl]methyl}-5-[(4-methoxybenzyl)oxy]-7,7-dimethyl-2-(piperidin-4-yl)-5,6,7,8-tetrahydroquinolineHCID 866824592-Chloro-5-[(1-methylpiperidin-4-yl)oxy]pyrimidine

生成物 1

HCID 86682465(-)-4-(4,4-Difluorocyclohexyl)-2-{1-[5-(difluoromethoxy)pyrimidin-2-yl]piperidin-4-yl}-3-{fluoro[4-(trifluoromethyl)phenyl]methyl}-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol

実験手順

Reactions similar to those of Reference Example 29 and Example 38 were performed except for using 2-chloro-5-(difluoromethoxy)pyrimidine, which was prepared by a method similar to that of Reference Example 32, instead of 2-chloro-5-[(1-methylpiperidin-4-yl)oxy]pyrimidine, and from 102 mg (151 μmol) of (−)-4-(4,4-Difluorocyclohexyl)-3-{fluoro[4-(trifluoromethyl)phenyl]methyl}-5-[(4-methoxybenzyl)oxy]-7,7-dimethyl-2-(piperidin-4-yl)-5,6,7,8-tetrahydroquinoline, which was prepared by a method similar to that of Reference Example 10, 52 mg of the title compound was obtained as a white solid (yield: 49%).

後処理

  1. customwas prepared by a method similar to that of Reference Example 32

出典と根拠

ORDレコード
ord-38a8493eb3d34023ad8df8bedead4093
出典データセット
uspto-grants-2015_11
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US09187450B2

反応ノート

読み込み中…

このページの内容参加物実験手順後処理出典と根拠反応ノート